

#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

de la Monte *et al.*

Appl. No. 09/380,203

(National Phase of Int'l. Appl. No.
PCT/US98/03685)International Filing Date:
February 26, 1998For: **Transgenic Animals and Cell Lines
for Screening Drugs Effective for
the Treatment or Prevention of
Alzheimer's Disease**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0609.4370001/RWE/KKV

Information Disclosure StatementAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Document AL1, European Patent No. 0 263 740, is in a foreign language. No English translation is readily available. This document appears to disclose new conjugates of anti-sense nucleic acid and polypeptide used to inhibit gene expression, especially that of specific viral genes. A copy of an English language abstract of this document is attached herein as Document AS5 to satisfy Applicants' duty to provide a concise statement of relevance under 37 C.F.R. § 1.98(a)(3). (1135 OG 14, column 1, second paragraph, Feb. 4, 1992).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This Information Disclosure Statement is being filed either within three months of the U.S. filing date or before the mailing date of a first Office Action on the merits. Thus, no statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Kristin K. Vidovich
Attorney for Applicants
Registration No. 41,448

Date: 12/3/99
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600
P:\USERS\DTWEI\0609\4370001\IDS\Plead.wpd
SKGF Rev. 1/26/98 clp